Researchers have identified the SHP protein as a key regulator that suppresses cartilage-degrading enzymes and slows osteoarthritis progression.

Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who ...

A major report highlighting how engineering biology can drive economic growth, improved health outcomes and environmental ...

This clinical-stage biotech develops bifunctional antibody therapies targeting solid tumors for oncology providers and ...

RB042 Phase 1 trial advances into multiple ascending dose study cohorts, demonstrating safety and tolerability to date. Dr.

Phase 3 AD trial: 85% of patients enrolled; full enrollment on track in summer 2026PD open-label extension (OLE) study: 40% of patients enrolled; full enrollment on track in fourth quarter 2026New Dru ...

Neurizon receives Bellberry HREC approval for phase 1 NUZ-001 oral liquid formulation study: Melbourne, Australia Friday, May 15, 2026, 16:00 Hrs [IST] Neurizon Therapeutics Limit ...

Regenxbio announces positive results from pivotal phase III AFFINITY DUCHENNE study of RGX-202 to treat Duchenne muscular dystrophy: Rockville, Maryland Friday, May 15, 2026, 14:0 ...

First Tracks launched April 20th with a two-year cash-runway to advance ANB033 through celiac disease and eosinophilic ...

The court also ordered its senior registrar to keep the paper-book and the loose documents provided by the petitioner in a ...

Operator: Greetings, and welcome to the PDS Biotech First Quarter 2026 Earnings Conference Call. [Operator Instructions] It ...

Phase 1 proof-of-mechanism study of EQ504 on track to initiate in mid-2026, with data expected approximately six months thereafter Equillium appoints Snehal Naik, Ph.D., as Chief Development Officer ...